No Data
Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect?
Analysts Are Bullish on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Health Catalyst (HCAT)
Goldman Sachs Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Cuts Target Price to $43
JonesTrading Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $34
The Pediatric Brain Tumor Foundation Welcomes Day One Biopharmaceuticals' Renowned Dr. Samuel C. Blackman to Its Board of Directors
TD Cowen Initiates Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Announces Target Price $34
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
